MoonLake Immunotherapeutics (MLTX) Debt Ratio (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Debt Ratio came in at 0.25 in Q1 2026, up 73.16% year-on-year from 0.14 in Q1 2025, and up 41.66% quarter-over-quarter from 0.17 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Debt Ratio (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q1 2026.
- On a quarterly basis, Debt Ratio rose 73.16% year-over-year to 0.25 in Q1 2026; TTM through Mar 2026 was 0.25, a 73.16% increase from a year earlier, with the FY2025 full-year figure at 0.17, changed N/A from the prior year.
- Debt Ratio climbed to 0.25 in Q1 2026 per MLTX's latest filing, from 0.17 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.25 in Q1 2026 and bottomed at 0.14 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | 0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.25 |
| Dec 31, 2025 | 0.17 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.14 |
| Dec 31, 2021 | 1.55 |